Contact Us   |   Sign In   |   Join CAHR
Share |
Michael Leo, President
Michael Leo has been with Lundbeck Canada for 15 years and is currently the Senior Manager, Market Access for Federal, ON & West public payers. Previous roles at Lundbeck include regional and district sales management as well as product management assignments in Canada and public affairs at Lundbeck's global headquarters in Denmark. Mike has held numerous other positions in the pharmaceutical industry at SmithKline Beecham, HoechstMarionRoussel and Searle. Mike has been a member of the Board of Directors of the Canadian Association for Healthcare Reimbursement for 5 years and is a former board member of the Government Relations Institute of Canada (GRIC). Mike holds an MBA from the University of Ottawa and a B.Com from Carleton University.
Michael Leo
Ferg Mills, Vice President
Ferg Mills is a health economist and Director of Strategic Consulting at Innomar Strategies, where he heads the HEOR team. Ferg's academic interests focus on Canadian pharmaceutical policy, in particular on HTA processes and institutions. Ferg's areas of expertise include decision analytic modeling, clinical trial analysis and budget impact analysis, and he regularly presents at industry events on these subjects. Ferg's team develops reimbursement strategies and submission dossiers for the Common Drug Review and the Pan-Canadian Oncology Drug Review. Ferg holds a BA in Economics from the University of Toronto and a MSc in Health Economics from the University of York.
Ferg Mills
Julia Brown, Immediate Past President
Julia has been with Janssen Inc. for 14 years and is currently the Vice President of Government Affairs and Market Access. Previous roles at Janssen include National Director of Government and Community Relations, Director of Health Economics and Reimbursement and Director of Government Relations, Ontario/Atlantic. Julia also serves as the President of the Canadian Association for Healthcare Reimbursement (CAHR) and been a member of the CAHR Board of Directors for 11 years. She served as a Chief of Staff in the Ontario Provincial Government from 1997 to 2003 in the portfolios of Municipal Affairs and Housing, Management Board and Natural Resources. Julia has additional experience in the Federal Government, the not-for-profit sector and textile manufacturing and holds a B.A. in Political Science from Carleton University. She resides in Toronto with her three daughters and enjoys skiing, golfing and travel.
Julia Brown
Robert Kamino, Past President
In nearly 40 years in the health care industry, Bob has held senior positions in marketing, market access, intellectual property, business development, sales, and quality assurance. He has worked for a number of large pharmaceutical firms, most recently with Janssen-Ortho Inc. where he was engaged in pricing, intellectual property and reimbursement. Prior to that he was with Janssen Pharmaceuticals both in Canada and at Janssen's world headquarters in Beerse, Belgium; prior to that he was employed by CIBA-Geigy Canada Inc., E. Merck AG and Glaxo Laboratories Ltd. At present, Bob works with pharmaceutical companies in Canada and abroad providing advice and counsel based on IMS Brogan's extensive data holdings and research capabilities.
Robert Kamino
Rebecca Szilagyi-Vieria, Secretary-Treasurer
Rebecca Szilagyi-Vieria has recently taken on a new role as the Manager of Pricing and Trade Strategy for GlaxoSmithKline. Prior to this Rebecca lead the Strategic Consulting Team at Innomar Strategies where her focus was obtaining optimal access for clients by developing strong market access strategies focusing on pricing, reimbursement and patient assistance programs. She has experience working in primary care, specialty drugs, oncology and orphan diseases.

Rebecca began her career in pharmacovigilance for consumer health products before moving on to the federal government. She held roles as an economist with the PMPRB and as a regulatory analyst within Health Canada. She has been a volunteer with CAHR for three years and holds a Masters degree in Public Health Policy and a B.Sc. in Biomedical Science.
Rebecca Szilagyi-Vieria
Matthew Brougham, Director at Large
Matthew specialises in scientific, economic and financial analysis essential for efficient and equitable resource allocation. He has applied this expertise to the health sector (in particular, drug plan management), tax and transfer policy, transport, and fisheries management and been an analyst/advisor and/or decision maker within public sector agencies since 1988. His professional background includes senior government positions in New Zealand and Canada including Vice President of CADTH (Canada's health technology assessment agency) and Chief Executive of PHARMAC (New Zealand’s universal drug plan).

Matthew holds science degrees in Zoology (University of Otago, NZ) and Natural resource management (Canterbury University, NZ) and a post graduate diploma in Health Economics (University of Tromso, Norway). His continuing professional education has focused on evaluation techniques, and business management and leadership.
Matthew Brougham
Bill Dempster, Director, Events & Education
As CEO of 3Sixty Public Affairs, Bill Dempster develops and implements high-impact government relations, policy and strategies for clients in the health and life sciences sector. Bill draws on his business, legal, non-profit and government experience to help clients find mutually beneficial solutions to complex regulatory, reimbursement and policy problems. Previously, Bill was a member of the federal relations and health policy team at Pfizer Canada. His experience also includes working for a Member of Parliament, the United Nations and major Canadian law firms. Bill is fluently bilingual, and has degrees in history (King's College, University of Western Ontario), law (Queen's University), and a Masters of Arts in international affairs (Norman Paterson School of International Affairs, Carleton University). He was called to the Bar of Ontario in 2002.
Bill Dempster
Hélène Lalonde, Director at Large
With more than 20 years of experience in the innovative and generic pharmaceutical sectors, Hélène currently leads the market access and pricing functions at Pendopharm, the branded division of Pharmascience Canada Inc. This role has allowed her to gain expertise in a highly diversified range of products from single source generic, medical devices, first in class switches from prescription brand to OTC, biosimilars and innovative drugs. Hélène also has extensive experience in helping develop business models to in-license existing molecules, as such the assessment of business opportunities for Canada. As the company's sole market access professional, she is responsible for all activities related to CADTH/INESSS, PMPRB, pCPA/PLA negotiations, and public/private payers.
Hélène Lalonde
James LeBrocq, Director, Membership
James is presently Senior Manager Marketing and Business Development at McKesson Canada, with a focus on the Specialty Division, a position he has held for the past four years. James spent 7 years on the Board of Directors at CAHR, as Director for Membership, taking a break in 2014. James helped initiate the Market Access 101 program at CAHR, and led the CMAP initiative, and has been involved recently at CAHR on the Advisory Board. James has over 25 years' experience in the pharmaceutical industry with firms like AmerisourceBergen, Schering Plough, Aventis as well as 15 years at Innomar/AmersourceBergen prior to his role at McKesson.
James LeBrocq
Mark Levine, Director, Communications
Mark Levine is Director, Offering Management, Strategic Information Services (SIS) at QunitilesIMS where he is responsible for the planning, editorial management and production of SIS products and services, including PharmaFocus, Provincial Reimbursement Advisor (PRA Weekly and Quarterly), Monthly Market Monitor, The Weekly Capsule, and related client briefings and events.

Mark is a communications professional with more than 20 years of practice within the broader health care community. He has worked with a diverse spectrum of health-related organizations including Community Care Access Centres in Ontario, the Canadian Diabetes Association and Canada Health Infoway. He has extensive experience in strategic planning and development, change management, stakeholder and client relations, marketing, publishing, editing, media relations and web technologies, and has counselled Boards, senior executives and front-line employees in strategic communications planning and best practices. A former journalist, Mark has also written for major Canadian newspapers and was managing editor, then publisher, of the Journal of the Ontario Dental Association.
Mark Levine
Arvind Mani, Director, Partnerships
Arvind Mani is Managing Director at Mani & O'Quinn Reimbursement Strategy Experts (MORSE) Consulting Inc. – a consultancy focused on developing creative solution for challenging reimbursement problems. Arvind has more than 20 years of work experience in industry, associations (pharmaceutical and pharmacy), and consulting. He has an in-depth understanding of pharmaceutical industry issues and is continually looking for opportunities to shed light on emerging issues of importance to the pharmaceutical market access community (e.g. public and private payer product listing agreements, international experience with biosimilars, orphan drugs, etc.). Arvind has the ability to establish positive and constructive relationships with pharmaceutical stakeholders through a strong sense of integrity and trust.
Arvind Mani
Myra Wang, Director at Large
Myra Wang is a Clinical Epidemiologist within the Evidence Development and Standards branch at Health Quality Ontario. In her role, she conducts clinical evidence reviews and health technology assessments on non-drug health technologies to support evidence-based decision-making, including recommendations on whether a particular health technology should be publicly funded in Ontario. In addition, she has helped develop other provincial evidence-based products such as clinical handbooks and quality standards. Myra also worked at the Institute for Clinical Evaluative Sciences on health services research focused on the use of electronic medical record data, and at other institutions on primary research projects. Myra holds a BSc in Anatomy and Cell Biology from McGill University, and a MSc in Pharmaceutical Sciences from the University of British Columbia.
Myra Wang
Membership Software Powered by YourMembership  ::  Legal